Roivant Sciences

Contributing Author

Recent Articles by Roivant Sciences

Oct-27	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 ROIV GlobeNewswire
Sep-17	Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM) ROIV GlobeNewswire
Sep-11	Roivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List ROIV GlobeNewswire
Sep-03	Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients ROIV GlobeNewswire
Aug-11	Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update ROIV GlobeNewswire
Jul-28	Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025 ROIV GlobeNewswire
Jun-09	Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis ROIV GlobeNewswire
May-29	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update ROIV GlobeNewswire
May-15	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025 ROIV GlobeNewswire